Foundayo (orforglipron): doses, side effects, and what to track

Introduction

Foundayo is orforglipron, a once-daily oral GLP-1 receptor agonist approved by the FDA for long-term weight management in eligible adults. Unlike oral semaglutide, the Foundayo label allows the tablet to be taken with or without food, and it does not require a fasting window. The FDA prescribing information is the source for the current dose steps, warnings, and missed-dose instructions.

How Foundayo differs from injectable GLP-1 medications

Orforglipron is a small-molecule GLP-1 receptor agonist. Foundayo is taken as a tablet once daily, while Ozempic, Wegovy, Mounjaro, and Zepbound are commonly used as weekly injections under their own product labels. Foundayo should not be combined with another GLP-1 receptor agonist unless a clinician gives specific instructions.

The practical difference is the routine. Foundayo can be taken at any time of day with or without food, but daily dosing creates more opportunities to forget a tablet. Swallow the tablet whole and do not take more than one tablet per day.

Foundayo dosing follows monthly steps

The FDA prescribing information starts Foundayo at 0.8 mg once daily. After at least 30 days, the label allows an increase to 2.5 mg, then 5.5 mg. Further increases to 9 mg, 14.5 mg, or 17.2 mg can occur after at least 30 days at the current dose when treatment response and tolerability support the change.

These are label-based dose options, not a reason to change your own dose. Your prescriber may delay an increase, choose a different step, or decide that a higher dose is not appropriate. Never double a missed dose.

Foundayo side effects need a personal timeline

The most useful question is not only whether a symptom appears, but when it appears relative to the dose step. The Foundayo label lists gastrointestinal effects such as nausea, diarrhea, constipation, vomiting, indigestion, abdominal pain, and belching. It also lists headache, fatigue, and hair loss among adverse reactions.

Contact your healthcare provider for persistent vomiting, severe abdominal pain, symptoms of dehydration, or a symptom that prevents you from eating or drinking. The label also includes warnings about serious hypersensitivity reactions and other risks. Keep your prescriber informed rather than treating the app record as a diagnosis.

What to track during the first month

During the first 30 days, record the information that helps you and your provider evaluate tolerability:

• Dose and time: Record whether you took the tablet and when.
• Digestive symptoms: Note nausea, vomiting, diarrhea, constipation, abdominal discomfort, and reflux.
• Appetite and fullness: Track changes without assuming that less appetite always means adequate nutrition.
• Hydration and meals: These details can help put fatigue, dizziness, or constipation in context.
• Weight trend: Look at a multi-week trend rather than reacting to a single measurement.

The label says that if 7 or more consecutive doses are missed, the dose-escalation schedule should be restarted at a lower dose. Ask your prescriber what to do after a missed dose or interruption.

Track Foundayo with Shotsy

Shotsy supports daily Foundayo logging, reminders, dose-level charts, side-effect notes, weight tracking, and estimated medication-level charts. The estimate is based on pharmacokinetic information and is not a blood test. It can help organize a pattern for a provider conversation, but it cannot tell you whether a dose should change.

Conclusion

Foundayo offers a daily oral GLP-1 routine with no fasting requirement. Its label uses dose steps that last at least 30 days, and side effects should be evaluated alongside the dose, appetite, hydration, and weight trend. Track consistently, use the FDA label as the medication reference, and make every treatment decision with your prescriber.

For related reading, see the first-month guide, oral Wegovy guide, and GLP‑1 side-effects overview.